WEDNESDAY, April 19, 2023 (HealthDay News) -- For nonhospitalized patients with COVID-19 at high risk for clinical progression, amubarvimab plus romlusevimab is safe and reduces the risk for hospitalization and/or death, according to a study published online April 18 in…
